Lifevantage (NASDAQ:LFVN) Director Judd Dayton Purchases 18,097 Shares of Stock

Lifevantage Corporation (NASDAQ:LFVN) Director Judd Dayton bought 18,097 shares of Lifevantage stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $4.63 per share, with a total value of $83,789.11. Following the completion of the acquisition, the director owned 69,859 shares in the company, valued at approximately $323,447.17. The trade was a 34.96% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Judd Dayton also recently made the following trade(s):

• On Monday, March 2nd, Judd Dayton purchased 10,500 shares of Lifevantage stock. The stock was purchased at an average cost of $4.53 per share, for a total transaction of $47,565.00.
• On Thursday, February 26th, Judd Dayton acquired 4,600 shares of Lifevantage stock. The shares were purchased at an average cost of $4.58 per share, with a total value of $21,068.00.

Lifevantage Trading Down 2.8%

NASDAQ:LFVN opened at $4.52 on Tuesday. The firm has a market capitalization of $57.81 million, a PE ratio of 7.53 and a beta of 0.36. Lifevantage Corporation has a 1 year low of $3.90 and a 1 year high of $17.64. The firm’s fifty day simple moving average is $5.62 and its 200 day simple moving average is $7.86.

Lifevantage (NASDAQ:LFVN) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.07). Lifevantage had a net margin of 3.74% and a return on equity of 29.59%. The business had revenue of $48.93 million during the quarter, compared to analyst estimates of $54.40 million. Lifevantage has set its FY 2026 guidance at 0.600-0.800 EPS.

Lifevantage Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be given a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 4.0%. The ex-dividend date of this dividend is Monday, March 2nd. Lifevantage’s dividend payout ratio is currently 30.00%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a research report on Monday, December 29th. Loop Capital set a $5.00 price target on shares of Lifevantage in a research report on Thursday, February 5th. Lake Street Capital reaffirmed a “buy” rating on shares of Lifevantage in a research report on Thursday, February 5th. Finally, Wall Street Zen downgraded Lifevantage from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Institutional Trading of Lifevantage

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey bought a new position in Lifevantage during the second quarter worth about $31,000. JPMorgan Chase & Co. raised its holdings in shares of Lifevantage by 870.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock worth $66,000 after buying an additional 4,499 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Lifevantage in the 4th quarter worth approximately $74,000. Aristides Capital LLC bought a new position in shares of Lifevantage during the 4th quarter worth approximately $76,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Lifevantage in the 2nd quarter valued at $76,000. Institutional investors own 35.32% of the company’s stock.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.